

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An Fc fragment as a drug carrier, which is an IgG Fc, a combination thereof or a hybrid thereof, wherein the Fc fragment is covalently linked to a drug through a non-peptide linker, wherein the non-peptide linker comprises polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, dextran, polyvinyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), a lipid polymer, a chitin, hyaluronic acid, or a combination thereof.

2. (Original) The Fc fragment as set forth in claim 1, wherein the IgG is IgG2 or IgG4.

3. (Original) The Fc fragment as set forth in claim 2, wherein the IgG is IgG4.

4. (Original) The Fc fragment as set forth in claim 1, which is aglycosylated.

5. (Original) The Fc fragment as set forth in claim 4, which is an aglycosylated IgG4 Fc fragment.

6. (Previously Presented) The Fc fragment as set forth in claim 5, wherein the aglycosylated IgG4 Fc fragment is human-derived.

7. (Previously Presented) The Fc fragment as set forth in claim 1, which comprises an amino acid sequence that is identical to the sequence set forth in SEQ ID NO. 8, 10 or 23.

8. (Withdrawn) A gene encoding the Fc fragment of claim 1.

9. (Withdrawn) The gene as set forth in claim 8, which has a nucleotide sequence represented by SEQ ID NO. 4,9 or 22.

10. (Withdrawn) A recombinant vector comprising the nucleotide sequence of claim 9.

11. (Withdrawn) A transformant transformed with the recombinant vector of claim 10.

12. (Withdrawn) A method of preparing an Fc fragment, comprising culturing the transformed microorganism of claim 11.

13. (Original) A pharmaceutical composition comprising the Fc fragment of claim 1.

14. (Canceled)

15. (New) The Fc fragment as set forth in claim 1, wherein the non-peptide linker comprises polyethylene glycol.